Forfour years, MIGAL [The Galilee Research Institute] researchers has been developing a vaccine against infectious bronchitis virus (IBV), which causes a bronchial disease affecting poultry. The poultry coronavirus has high genetic similarity to the human COVID-19, and that it uses the same infection mechanism. This could be a lucky break for minor modification of the existing vaccine to get a human vaccine approved in 90 days. The goal is to produce the vaccine during the next 8-10 weeks and to achieve safety approval in 90 days.
The effectiveness of the IBV chicken virus vaccine has been proven in preclinical trials carried out at the Veterinary Institute.
The vaccine is based on a new protein expression vector, which forms and secretes a chimeric soluble protein that delivers the viral antigen into mucosal tissues by self-activated endocytosis, causing the body to form antibodies against the virus.
Self-activated endocytosis is a cellular process in which substances are brought into a cell by surrounding the material with cell membrane, forming a vesicle containing the ingested material). The endocytosis mechanism is how the body forms antibodies against the virus. In pre-clinical (IN-VIVO) trials, MIGAL’s researchers have demonstrated that the oral vaccination induces high levels of specific anti-IBV antibodies.
The DNA of the novel coronavirus has high genetic similarity to the virus they have been using for testing. They use the same infection mechanism, which increases the likelihood of rapidly getting an effective human vaccine.
They are adjusting the DNA sequence and could have a vaccine in a few weeks.
“Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development,” MIGAL CEO David Zigdon said. The vaccine could “achieve safety approval in 90 days,” he said.
It will be an oral vaccine, making it particularly accessible to the general public.
Written By Brian Wang, Nextbigfuture.com